Drug Discovery

Twitter

Facebook

Copy Link

Key Facts

Key PlayersIsomorphic Labs, Recursion, Insilico

Top News

Reid Hoffman leaves Microsoft board after decade to go 'founder mode' with AI startup Manus

LinkedIn co-founder Reid Hoffman is stepping down from Microsoft's board after nearly a decade to focus on Manus, his AI-powered drug discovery startup. The company has raised over $50 million and is pursuing what Hoffman calls 'Move 37' AI to develop novel cancer treatments that supersede human creativity in chemistry.

Business6 sources

Reid Hoffman leaves Microsoft board after decade to go 'founder mode' with AI startup Manus

Business6 sources

Sanofi and Owkin deepen AI partnership with five-year K Pro license for drug development

Sanofi and Owkin have expanded their multi-year partnership to co-develop AI-driven biopharma agents through a five-year license for K Pro, Owkin's AI Scientist platform. The collaboration builds on their 90 million euro strategic partnership that began in 2021, focusing on oncology and immunology research. The new initiative aims to automate complex pharmaceutical research tasks across the drug development pipeline.

Technology2 sources

Sanofi and Owkin deepen AI partnership with five-year K Pro license for drug development

Technology2 sources

AI-designed vaccine passes first human trial, offering broad protection against coronaviruses

Researchers at the University of Cambridge successfully tested the world's first AI-designed vaccine in humans. The trial involved 39 volunteers and targeted multiple coronaviruses, including COVID-19 and SARS. The vaccine uses an AI-designed super-antigen that could provide lasting protection against entire virus families, even as they mutate, potentially transforming how we prepare for future pandemics.

Health11 sources

AI-designed vaccine passes first human trial, offering broad protection against coronaviruses

Health11 sources

Scientists use AI to create bacteria that run key cellular machinery on just 19 amino acids

Researchers at Columbia University and MIT have reengineered E. coli bacteria to operate core cellular machinery with just 19 amino acids instead of the universal 20. Using AI-guided protein design tools like AlphaFold, the team successfully removed isoleucine from 21 ribosomal proteins while maintaining robust cell growth. The breakthrough offers insights into early life forms and opens doors for engineering cells with novel capabilities.

Science3 sources

Scientists use AI to create bacteria that run key cellular machinery on just 19 amino acids

Science3 sources

Johnson & Johnson uses AI to slash drug development lead time by half

Johnson & Johnson is deploying artificial intelligence to cut drug development lead optimization time in half, according to CIO Jim Swanson. The pharmaceutical giant is also using AI to reduce clinical trial report preparation from 700 hours to just 15 minutes and optimize manufacturing processes, marking a significant shift in how the company approaches cancer treatment development.

Technology3 sources

Johnson & Johnson uses AI to slash drug development lead time by half

Technology3 sources

AI model designs new antibiotic in early tests, accelerating drug discovery against resistant bacteria

McMaster University researchers developed SyntheMol-RL, a generative AI model that explores 46 billion possible compounds to design antibiotics. In early tests, the AI created synthecin, a novel antibiotic that proved highly effective against drug-resistant staph infections in mouse models. The breakthrough demonstrates how AI can accelerate the slow, costly search for new antimicrobial medicines.

Science2 sources

AI model designs new antibiotic in early tests, accelerating drug discovery against resistant bacteria

Science2 sources

Merck and Google Cloud announce $1 billion AI partnership to transform drug development

Pharmaceutical giant Merck has announced a multi-year AI partnership with Google Cloud worth up to $1 billion. The collaboration will deploy Google's Gemini Enterprise platform across Merck's drug research, manufacturing, and regulatory operations. Merck has already cut reimbursement dossier preparation time and costs by half using Google's AI technology, and executives expect the partnership to last at least a decade.

Technology6 sources

Merck and Google Cloud announce $1 billion AI partnership to transform drug development

Technology6 sources

OpenAI unveils GPT-Rosalind AI model to accelerate drug discovery and life sciences research

OpenAI released GPT-Rosalind, its first domain-specific AI model built for life sciences research. Named after DNA pioneer Rosalind Franklin, the model aims to compress the 10-to-15-year drug development timeline by helping scientists synthesize evidence and generate biological hypotheses. Access is restricted through a trusted access program to enterprise partners including Amgen, Moderna, and Thermo Fisher Scientific.

Technology14 sources

OpenAI unveils GPT-Rosalind AI model to accelerate drug discovery and life sciences research

Technology14 sources

Helical raises $10M to turn bio foundation models into production drug discovery systems

London-based AI pharma startup Helical has secured $10 million in seed funding to build the infrastructure that turns biological foundation models into reproducible drug discovery workflows. Already in production with multiple top-20 pharmaceutical companies including Pfizer, the company aims to compress discovery timelines from years to weeks by bridging the gap between computational predictions and scientific decision-making.

Startups2 sources

Helical raises $10M to turn bio foundation models into production drug discovery systems

Startups2 sources

Novo Nordisk partners with OpenAI to accelerate drug discovery and obesity treatment development

Novo Nordisk announced a strategic partnership with OpenAI to integrate artificial intelligence across its operations, from drug discovery to manufacturing. The Danish drugmaker aims to analyze complex datasets, identify promising drug candidates faster, and regain competitive ground in the weight-loss drug market against rival Eli Lilly. Full integration is planned by the end of 2026.

Technology10 sources

Novo Nordisk partners with OpenAI to accelerate drug discovery and obesity treatment development

Technology10 sources

Anthropic acquires Coefficient Bio for $400M, deepening its push into drug discovery and life sciences

Anthropic has purchased stealth biotech AI startup Coefficient Bio in a $400 million all-stock deal, bringing a team of fewer than 10 former Genentech researchers into its healthcare division. Founded just eight months ago, the startup was building AI models to automate drug research and development planning, clinical regulatory strategy, and candidate identification—signaling Anthropic's intent to embed Claude deeply into pharmaceutical workflows.

Technology7 sources

Anthropic acquires Coefficient Bio for $400M, deepening its push into drug discovery and life sciences

Technology7 sources

AI-led selloff in contract research firms may overestimate disruption risk to CRO industry

Shares of contract research organizations like IQVIA, Medpace, and Charles River Laboratories tumbled after Anthropic's February AI agent launch sparked fears drugmakers could bring clinical trial work in-house. But industry experts argue the selloff misjudges how far artificial intelligence can replace core CRO capabilities like patient recruitment and global trial execution.

Business2 sources

AI-led selloff in contract research firms may overestimate disruption risk to CRO industry

Business2 sources

Australian man uses ChatGPT to design AI vaccine for his dog's cancer, catches Sam Altman's eye

Sydney-based AI consultant Paul Conyngham turned to ChatGPT, AlphaFold, and other AI tools to create a personalized experimental treatment for his rescue dog Rosie's terminal mast cell cancer. After months of AI-driven research and collaboration with university scientists, Rosie achieved partial remission with her largest tumor shrinking dramatically. OpenAI CEO Sam Altman praised the effort as an amazing story, though experts emphasize the need for rigorous scientific validation.

Technology3 sources

Australian man uses ChatGPT to design AI vaccine for his dog's cancer, catches Sam Altman's eye

Technology3 sources

Eli Lilly strikes $2.75 billion deal with Insilico Medicine to accelerate AI drug development

Eli Lilly has signed a major partnership with Hong Kong-based Insilico Medicine worth up to $2.75 billion to develop AI-powered drugs. The deal includes $115 million upfront and gives Lilly exclusive global rights to commercialize therapeutics designed by artificial intelligence. Insilico has already developed 28 drugs using generative AI, with nearly half in clinical stages.

Business13 sources

Eli Lilly strikes $2.75 billion deal with Insilico Medicine to accelerate AI drug development

Business13 sources

OpenAI Foundation commits $1 billion to tackle AI risks as Altman warns of societal threats

The OpenAI Foundation announced plans to invest $1 billion in 2026 across AI safety, healthcare research, and economic impact programs. CEO Sam Altman issued a stark warning that AI will introduce new societal threats no single company can handle alone, while the nonprofit arm of OpenAI named key leaders including co-founder Wojciech Zaremba to oversee AI resilience efforts.

Policy10 sources

OpenAI Foundation commits $1 billion to tackle AI risks as Altman warns of societal threats

Policy10 sources

Prev 1 2 345 Next